Eli Lilly and Co. (NYSE:LLY) has come out on top in a weight loss drug competition in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's (NYSE:NVO) Ozempic.
What Happened: The study, published on the JAMA Internal Medicine website, analyzed the electronic health records of approximately 41,000 obese or overweight patients who were prescribed these drugs.
It revealed that Mounjaro users experienced a mean loss in body weight of 5.9% at three months, compared to 3.6% for Ozempic users. At six months, the mean loss was 10.1% for Mounjaro users versus 5.8% for Ozempic users.
At 12 months, the mean body weight loss was 15.3% for Mounjaro users and 8.3% for Ozempic users. The risk of gastrointestinal adverse events was similar for both drugs.
Read Also: 'I Smoked It And I Felt The Disease Stop'
Mounjaro's active ingredient is tirzepatide, while Ozempic's is semaglutide. Lilly markets tirzepatide for diabetes as Mounjaro and for weight loss as Zepbound. Similarly, Novo markets semaglutide for diabetes as Ozempic and for weight loss as Wegovy. Both tirzepatide and semaglutide belong to a class of drugs known as GLP-1s.
Why It Matters: The findings come amid increasing scrutiny and competition in the weight loss drug market. Novo Nordisk has faced criticism over the high prices of its medications, Ozempic and Wegovy. The company has disclosed that it retains about 60% of the list price in the U.S. after rebates and fees.
Additionally, a recent observational study has linked Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, to a serious eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause vision loss. This condition, which involves a loss of blood flow to the optic nerve, was highlighted in a study.
Meanwhile, in response to the growing demand for GLP-1 drugs, Novo Nordisk announced a $4.1 billion investment to expand its U.S. manufacturing operations.
Price Action: Eli Lilly and Co. stock closed at $918.00, up 0.38% on Monday. In after-hours trading, the stock increased 0.30%. Year to date, Eli Lilly's stock has risen by 55.02%.
Meanwhile, Novo Nordisk closed at $143.07, up by 0.49% on the same day. Year to date, Novo Nordisk's stock has grown by $40.96, reflecting a 40.11% increase, according to data from Benzinga Pro.
- Why Is HilleVax Stock Trading Lower On Monday?
Image Via Shutterstock
This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote
Eli Lilly and Co.纽约证券交易所代码：LLY）在最近的一项研究中在减肥药物竞赛中名列前茅。该研究发现，服用礼来公司Mounjaro的患者比使用诺和诺德（纽约证券交易所代码：NVO）Ozempic的患者体重减轻得多。
发生了什么：这项研究发表在JAMA Internal Medicine网站上，分析了大约41,000名服用这些药物的肥胖或超重患者的电子健康记录。
报告显示，Mounjaro用户在三个月内的平均体重减轻了5.9％，而Ozempic用户的平均体重减轻了3.6％。六个月后，Mounjaro用户的平均损失为10.1％，而Ozempic用户的平均损失为5.8％。
在12个月时，Mounjaro用户的平均体重减轻为15.3％，Ozempic用户的平均体重减轻为8.3％。两种药物发生胃肠道不良事件的风险相似。
Mounjaro的活性成分是曲塞帕肽，而Ozempic的活性成分是索玛鲁肽。礼来公司以Mounjaro的名义销售用于糖尿病的替西帕肽，以Zepbound的名义销售用于减肥的替西帕肽。同样，Novo以Ozempic的名义销售用于糖尿病的西玛鲁肽，以Wegovy的名义销售用于减肥的西玛鲁肽。替塞帕肽和索玛鲁肽都属于一类被称为GLP-1的药物。
为何重要：这些发现是在减肥药市场的审查和竞争日益激烈的情况下得出的。诺和诺德因其药品Ozempic和Wegovy的高昂价格而受到批评。该公司透露，扣除回扣和费用后，它在美国保留了约60％的标价。
此外，最近的一项观察性研究将诺和诺德的 GLP-1 药物Ozempic和Wegovy与一种称为非动脉炎性前缺血性视神经病变（NAION）的严重眼部疾病联系起来，这种疾病可能导致视力丧失。一项研究强调了这种情况，它涉及流向视神经的血液流失。
同时，为了应对对 GLP-1 药物不断增长的需求，诺和诺德宣布投资41亿美元，以扩大其在美国的制造业务。
价格走势：礼来公司股价周一收于918.00美元，上涨0.38％。在盘后交易中，该股上涨了0.30％。今年迄今为止，礼来公司的股票已经上涨了55.02％。
同时，诺和诺德收于143.07美元，同日上涨0.49％。根据Benzinga Pro的数据，今年迄今为止，诺和诺德的股票增长了40.96美元，增长了40.11％。
